How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "1638"
  ["article_id"]=>
  string(4) "1638"
  [1]=>
  string(58) "Complications Higher Than Expected for Invasive Lung Tests"
  ["article_title"]=>
  string(58) "Complications Higher Than Expected for Invasive Lung Tests"
  [2]=>
  string(150) "WEDNESDAY, Jan. 16, 2019 -- The rates of complications after invasive diagnostic procedures for lung abnormalities are higher in the community setting"
  ["short_description"]=>
  string(150) "WEDNESDAY, Jan. 16, 2019 -- The rates of complications after invasive diagnostic procedures for lung abnormalities are higher in the community setting"
  [3]=>
  string(241) "WEDNESDAY, Jan. 16, 2019 -- The rates of complications after invasive diagnostic procedures for lung abnormalities are higher in the community setting than in clinical trials, according to a study published online Jan. 14 in JAMA Internal..."
  ["description"]=>
  string(241) "WEDNESDAY, Jan. 16, 2019 -- The rates of complications after invasive diagnostic procedures for lung abnormalities are higher in the community setting than in clinical trials, according to a study published online Jan. 14 in JAMA Internal..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "6"
  ["rss_id"]=>
  string(1) "6"
  [14]=>
  string(194) "https://www.drugs.com/news/complications-higher-than-expected-invasive-lung-tests-79780.html?utm_source=ddc&utm_medium=rss&utm_campaign=Complications+Higher+Than+Expected+for+Invasive+Lung+Tests"
  ["blog_url"]=>
  string(194) "https://www.drugs.com/news/complications-higher-than-expected-invasive-lung-tests-79780.html?utm_source=ddc&utm_medium=rss&utm_campaign=Complications+Higher+Than+Expected+for+Invasive+Lung+Tests"
  [15]=>
  string(19) "2019-01-16 20:00:29"
  ["add_date"]=>
  string(19) "2019-01-16 20:00:29"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-21 08:05:17"
  ["create_at"]=>
  string(19) "2019-01-21 08:05:17"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Complications Higher Than Expected for Invasive Lung Tests

WEDNESDAY, Jan. 16, 2019 -- The rates of complications after invasive diagnostic procedures for lung abnormalities are h

array(40) {
  [0]=>
  string(4) "1652"
  ["article_id"]=>
  string(4) "1652"
  [1]=>
  string(75) "Opioid prescribing highest in more deprived regions of England, study shows"
  ["article_title"]=>
  string(75) "Opioid prescribing highest in more deprived regions of England, study shows"
  [2]=>
  string(150) "Opioid prescribing in general practice is highest in the North West of England and the East Midlands, mirroring general geographical health inequaliti"
  ["short_description"]=>
  string(150) "Opioid prescribing in general practice is highest in the North West of England and the East Midlands, mirroring general geographical health inequaliti"
  [3]=>
  string(226) "Opioid prescribing in general practice is highest in the North West of England and the East Midlands, mirroring general geographical health inequalities, a study published in the International Journal of Drug Policy has found."
  ["description"]=>
  string(226) "Opioid prescribing in general practice is highest in the North West of England and the East Midlands, mirroring general geographical health inequalities, a study published in the International Journal of Drug Policy has found."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "11"
  ["rss_id"]=>
  string(2) "11"
  [14]=>
  string(153) "https://www.pharmaceutical-journal.com/news-and-analysis/news/opioid-prescribing-highest-in-more-deprived-regions-of-england-study-shows/20206014.article"
  ["blog_url"]=>
  string(153) "https://www.pharmaceutical-journal.com/news-and-analysis/news/opioid-prescribing-highest-in-more-deprived-regions-of-england-study-shows/20206014.article"
  [15]=>
  string(19) "2019-01-16 19:57:00"
  ["add_date"]=>
  string(19) "2019-01-16 19:57:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-21 08:05:18"
  ["create_at"]=>
  string(19) "2019-01-21 08:05:18"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Opioid prescribing highest in more deprived regions of England, study shows

Opioid prescribing in general practice is highest in the North West of England and the East Midlands, mirroring general 

array(40) {
  [0]=>
  string(4) "1653"
  ["article_id"]=>
  string(4) "1653"
  [1]=>
  string(60) "Increased intensity plus adherence maximises statin benefits"
  ["article_title"]=>
  string(60) "Increased intensity plus adherence maximises statin benefits"
  [2]=>
  string(150) "High adherence to intensive lipid-lowering therapy provides the greatest risk reduction for cardiovascular events, a study in JAMA Network Open has sh"
  ["short_description"]=>
  string(150) "High adherence to intensive lipid-lowering therapy provides the greatest risk reduction for cardiovascular events, a study in JAMA Network Open has sh"
  [3]=>
  string(154) "High adherence to intensive lipid-lowering therapy provides the greatest risk reduction for cardiovascular events, a study in JAMA Network Open has shown."
  ["description"]=>
  string(154) "High adherence to intensive lipid-lowering therapy provides the greatest risk reduction for cardiovascular events, a study in JAMA Network Open has shown."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "11"
  ["rss_id"]=>
  string(2) "11"
  [14]=>
  string(152) "https://www.pharmaceutical-journal.com/news-and-analysis/research-briefing/increased-intensity-plus-adherence-maximises-statin-benefits/20205995.article"
  ["blog_url"]=>
  string(152) "https://www.pharmaceutical-journal.com/news-and-analysis/research-briefing/increased-intensity-plus-adherence-maximises-statin-benefits/20205995.article"
  [15]=>
  string(19) "2019-01-16 18:54:00"
  ["add_date"]=>
  string(19) "2019-01-16 18:54:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-21 08:05:18"
  ["create_at"]=>
  string(19) "2019-01-21 08:05:18"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Increased intensity plus adherence maximises statin benefits

High adherence to intensive lipid-lowering therapy provides the greatest risk reduction for cardiovascular events, a stu

array(40) {
  [0]=>
  string(4) "1852"
  ["article_id"]=>
  string(4) "1852"
  [1]=>
  string(97) "Lipotype announces “Lipidomics Excellence Award” for Breakthrough Lipidomics Projects"
  ["article_title"]=>
  string(97) "Lipotype announces “Lipidomics Excellence Award” for Breakthrough Lipidomics Projects"
  [2]=>
  string(150) "Call for Applications open till 30 March, 2019Dresden/Germany, 16 January, 2019. The international scientific community is called to submit applicatio"
  ["short_description"]=>
  string(150) "Call for Applications open till 30 March, 2019Dresden/Germany, 16 January, 2019. The international scientific community is called to submit applicatio"
  [3]=>
  string(574) "Call for Applications open till 30 March, 2019Dresden/Germany, 16 January, 2019. The international scientific community is called to submit applications for the premiere of the world’s first award for cutting edge contributions to the progress of life sciences through lipidomics, the 2019 “Lipidomics Excellence Award” (LEA) until 30 March, 2019. Prof. Dr. Kai Simons, Professor and Director Emeritus at Max-Planck-Institute for Molecular Cell Biology and Genetics Dresden and Founder and CEO of Lipotype, explains: “Blood...&#nl&#nlSource: RealWire"
  ["description"]=>
  string(574) "Call for Applications open till 30 March, 2019Dresden/Germany, 16 January, 2019. The international scientific community is called to submit applications for the premiere of the world’s first award for cutting edge contributions to the progress of life sciences through lipidomics, the 2019 “Lipidomics Excellence Award” (LEA) until 30 March, 2019. Prof. Dr. Kai Simons, Professor and Director Emeritus at Max-Planck-Institute for Molecular Cell Biology and Genetics Dresden and Founder and CEO of Lipotype, explains: “Blood...&#nl&#nlSource: RealWire"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "64"
  ["rss_id"]=>
  string(2) "64"
  [14]=>
  string(79) "http://www.realwire.com/releases/Lipotype-announces-Lipidomics-Excellence-Award"
  ["blog_url"]=>
  string(79) "http://www.realwire.com/releases/Lipotype-announces-Lipidomics-Excellence-Award"
  [15]=>
  string(19) "2019-01-16 18:00:00"
  ["add_date"]=>
  string(19) "2019-01-16 18:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-04-22 13:42:54"
  ["create_at"]=>
  string(19) "2019-04-22 13:42:54"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Lipotype announces “Lipidomics Excellence Award” for Breakthrough Lipidomics P

Call for Applications open till 30 March, 2019Dresden/Germany, 16 January, 2019. The international scientific community 

array(40) {
  [0]=>
  string(4) "1654"
  ["article_id"]=>
  string(4) "1654"
  [1]=>
  string(72) "Data on NHS medicinal cannabis prescribing expected by end of March 2019"
  ["article_title"]=>
  string(72) "Data on NHS medicinal cannabis prescribing expected by end of March 2019"
  [2]=>
  string(152) "NHS England is monitoring the prescribing of cannabis-based products for medicinal use, with the first data expected by the end of March 2019, health"
  ["short_description"]=>
  string(152) "NHS England is monitoring the prescribing of cannabis-based products for medicinal use, with the first data expected by the end of March 2019, health"
  [3]=>
  string(179) "NHS England is monitoring the prescribing of cannabis-based products for medicinal use, with the first data expected by the end of March 2019, health minister Steve Brine says."
  ["description"]=>
  string(179) "NHS England is monitoring the prescribing of cannabis-based products for medicinal use, with the first data expected by the end of March 2019, health minister Steve Brine says."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "11"
  ["rss_id"]=>
  string(2) "11"
  [14]=>
  string(151) "https://www.pharmaceutical-journal.com/news-and-analysis/news/data-on-nhs-medicinal-cannabis-prescribing-expected-by-end-of-march-2019/20205989.article"
  ["blog_url"]=>
  string(151) "https://www.pharmaceutical-journal.com/news-and-analysis/news/data-on-nhs-medicinal-cannabis-prescribing-expected-by-end-of-march-2019/20205989.article"
  [15]=>
  string(19) "2019-01-16 17:44:00"
  ["add_date"]=>
  string(19) "2019-01-16 17:44:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-21 08:05:18"
  ["create_at"]=>
  string(19) "2019-01-21 08:05:18"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Data on NHS medicinal cannabis prescribing expected by end of March 2019

NHS England is monitoring the prescribing of cannabis-based products for medicinal use, with the first data expected 

array(40) {
  [0]=>
  string(4) "1581"
  ["article_id"]=>
  string(4) "1581"
  [1]=>
  string(101) "bioLIVE China 2019 to be Newly Upgraded, to Lead the Development of the Bio-Pharma Technology in Asia"
  ["article_title"]=>
  string(101) "bioLIVE China 2019 to be Newly Upgraded, to Lead the Development of the Bio-Pharma Technology in Asia"
  [2]=>
  string(5097) "
The bio-pharma industry has entered the new stage of rapid development in recent years with the continuous development of the cutting-edge biological technology and the emerging and marketing of new targeted drugs and cell therapies, etc.
From the perspective of global market size, sales of the global biotech drugs are expected to account for more than one third of all the sales revenue of pharmaceutical products by 2020. According to the statistics of InSight, in 2017, the biological drug applications reached the highest level in China in recent 5 years, with a total of 616. And Frost & Sullivan forecasts that the biological drug market size will reach RMB 326.9 billion in China in 2021, with the growth rate ranking high in the world.

The bio-pharma display platform with 7 years of historical accumulation in China—BioPh China will be newly upgraded into bioLIVE China on June 18-20, 2019. bioLIVE China 2019 will focus on life science, biotechnology, and innovative drugs, lead the bio-medicine technology innovation and industry development, and interact with industry high-end conferences. Together with CPhI China 2019 in SNIEC, bioLIVE China will jointly create a leading whole-industry-chain annual gala of the pharmaceutical industry in Asia
To comprehensively showcase the industry’s leading technologies, with the participation of 150+ bio-pharma exhibitors
bioLIVE China 2019 will gather top biopharmaceutical products and R&D information inside and outside China, and is expected to attract 150+ well-known enterprises including 3SBio, Sinobioway, Dongbao Pharmaceutical, Gan & Lee Pharmaceuticals, GenScript Biotech, Hualan Bio, Hybio Pharmaceutical, and Frontier Biotechnologies to join. It is becoming a first choice for bio-pharma enterprises to publicize brands and expand markets, by virtue of the exhibition platform advantages of high internationalization degree and full coverage of the pharmaceutical industry!

bioLIVE China 2019, a leader in Asian biopharmaceutical exhibitions, will centrally showcase advanced technologies in the three areas: biological products and emerging therapies; bioprocessing, manufacturing and solutions; and biotechnology and R&D services. It is expected to gather more than 20,000 Chinese and overseas professional buyers and researchers in Shanghai, to provide professionals in biotechnology, new drug R&D, and pharmaceutical investment areas, etc. with an industry-leading platform for information exchange and international trade expansion.
To gather Chinese and overseas experts, and initiate a top summit forum of the bio-pharma industry
bioLIVE China will enter into deep cooperation with international professional biotechnology organizations, bio-pharma enterprises, and high-end bio-pharma technological and financial talents in 2019, to roll out the industry top summit forum—Bio S&T which will focus on the new scientific thoughts (Science) and new technological developments (Technology) of bio-pharmaceuticals, to provide the rapidly developing bio-pharma industry a platform to regularly showcase itself and get the latest information of the industry.

Concurrently with the exhibition, Bio S&T will hold three-day high-end biotechnology meetings, to keep track of the development trends of the bio-medicine industry in recent years; it will invite over 30 senior pharmaceutical experts inside and outside China to form a luxury speaker lineup to combine meeting and exhibition through the three topics of therapeutic monoclonal antibodies, GMP production of macromolecular biopharmaceutical products, and biotechnology investment, and will gather individuals and enterprises, and upstream and downstream experts and users to conduct multidimensional exchanges and interactions; it will drive development through technological innovation, and achieve win-win through mutually beneficial cooperation, to boost the bio-pharma industry to flourish.

Visit the exhibition website http://www.cphi-china.cn/biolive/ennow to register online and join the annual event of the biopharmaceutical industry, and have face-to-face exchanges with the industry giants!

bioLIVE China 2019 
June 18-20, 2019, SNIEC, Shanghai, China
Organizer: UBM EMEA, CCCMHPIE
Co-organizer: UBM Sinoexpo
"
  ["short_description"]=>
  string(5097) "
The bio-pharma industry has entered the new stage of rapid development in recent years with the continuous development of the cutting-edge biological technology and the emerging and marketing of new targeted drugs and cell therapies, etc.
From the perspective of global market size, sales of the global biotech drugs are expected to account for more than one third of all the sales revenue of pharmaceutical products by 2020. According to the statistics of InSight, in 2017, the biological drug applications reached the highest level in China in recent 5 years, with a total of 616. And Frost & Sullivan forecasts that the biological drug market size will reach RMB 326.9 billion in China in 2021, with the growth rate ranking high in the world.

The bio-pharma display platform with 7 years of historical accumulation in China—BioPh China will be newly upgraded into bioLIVE China on June 18-20, 2019. bioLIVE China 2019 will focus on life science, biotechnology, and innovative drugs, lead the bio-medicine technology innovation and industry development, and interact with industry high-end conferences. Together with CPhI China 2019 in SNIEC, bioLIVE China will jointly create a leading whole-industry-chain annual gala of the pharmaceutical industry in Asia
To comprehensively showcase the industry’s leading technologies, with the participation of 150+ bio-pharma exhibitors
bioLIVE China 2019 will gather top biopharmaceutical products and R&D information inside and outside China, and is expected to attract 150+ well-known enterprises including 3SBio, Sinobioway, Dongbao Pharmaceutical, Gan & Lee Pharmaceuticals, GenScript Biotech, Hualan Bio, Hybio Pharmaceutical, and Frontier Biotechnologies to join. It is becoming a first choice for bio-pharma enterprises to publicize brands and expand markets, by virtue of the exhibition platform advantages of high internationalization degree and full coverage of the pharmaceutical industry!

bioLIVE China 2019, a leader in Asian biopharmaceutical exhibitions, will centrally showcase advanced technologies in the three areas: biological products and emerging therapies; bioprocessing, manufacturing and solutions; and biotechnology and R&D services. It is expected to gather more than 20,000 Chinese and overseas professional buyers and researchers in Shanghai, to provide professionals in biotechnology, new drug R&D, and pharmaceutical investment areas, etc. with an industry-leading platform for information exchange and international trade expansion.
To gather Chinese and overseas experts, and initiate a top summit forum of the bio-pharma industry
bioLIVE China will enter into deep cooperation with international professional biotechnology organizations, bio-pharma enterprises, and high-end bio-pharma technological and financial talents in 2019, to roll out the industry top summit forum—Bio S&T which will focus on the new scientific thoughts (Science) and new technological developments (Technology) of bio-pharmaceuticals, to provide the rapidly developing bio-pharma industry a platform to regularly showcase itself and get the latest information of the industry.

Concurrently with the exhibition, Bio S&T will hold three-day high-end biotechnology meetings, to keep track of the development trends of the bio-medicine industry in recent years; it will invite over 30 senior pharmaceutical experts inside and outside China to form a luxury speaker lineup to combine meeting and exhibition through the three topics of therapeutic monoclonal antibodies, GMP production of macromolecular biopharmaceutical products, and biotechnology investment, and will gather individuals and enterprises, and upstream and downstream experts and users to conduct multidimensional exchanges and interactions; it will drive development through technological innovation, and achieve win-win through mutually beneficial cooperation, to boost the bio-pharma industry to flourish.

Visit the exhibition website http://www.cphi-china.cn/biolive/ennow to register online and join the annual event of the biopharmaceutical industry, and have face-to-face exchanges with the industry giants!

bioLIVE China 2019 
June 18-20, 2019, SNIEC, Shanghai, China
Organizer: UBM EMEA, CCCMHPIE
Co-organizer: UBM Sinoexpo
"
  [3]=>
  string(5097) "
The bio-pharma industry has entered the new stage of rapid development in recent years with the continuous development of the cutting-edge biological technology and the emerging and marketing of new targeted drugs and cell therapies, etc.
From the perspective of global market size, sales of the global biotech drugs are expected to account for more than one third of all the sales revenue of pharmaceutical products by 2020. According to the statistics of InSight, in 2017, the biological drug applications reached the highest level in China in recent 5 years, with a total of 616. And Frost & Sullivan forecasts that the biological drug market size will reach RMB 326.9 billion in China in 2021, with the growth rate ranking high in the world.

The bio-pharma display platform with 7 years of historical accumulation in China—BioPh China will be newly upgraded into bioLIVE China on June 18-20, 2019. bioLIVE China 2019 will focus on life science, biotechnology, and innovative drugs, lead the bio-medicine technology innovation and industry development, and interact with industry high-end conferences. Together with CPhI China 2019 in SNIEC, bioLIVE China will jointly create a leading whole-industry-chain annual gala of the pharmaceutical industry in Asia
To comprehensively showcase the industry’s leading technologies, with the participation of 150+ bio-pharma exhibitors
bioLIVE China 2019 will gather top biopharmaceutical products and R&D information inside and outside China, and is expected to attract 150+ well-known enterprises including 3SBio, Sinobioway, Dongbao Pharmaceutical, Gan & Lee Pharmaceuticals, GenScript Biotech, Hualan Bio, Hybio Pharmaceutical, and Frontier Biotechnologies to join. It is becoming a first choice for bio-pharma enterprises to publicize brands and expand markets, by virtue of the exhibition platform advantages of high internationalization degree and full coverage of the pharmaceutical industry!

bioLIVE China 2019, a leader in Asian biopharmaceutical exhibitions, will centrally showcase advanced technologies in the three areas: biological products and emerging therapies; bioprocessing, manufacturing and solutions; and biotechnology and R&D services. It is expected to gather more than 20,000 Chinese and overseas professional buyers and researchers in Shanghai, to provide professionals in biotechnology, new drug R&D, and pharmaceutical investment areas, etc. with an industry-leading platform for information exchange and international trade expansion.
To gather Chinese and overseas experts, and initiate a top summit forum of the bio-pharma industry
bioLIVE China will enter into deep cooperation with international professional biotechnology organizations, bio-pharma enterprises, and high-end bio-pharma technological and financial talents in 2019, to roll out the industry top summit forum—Bio S&T which will focus on the new scientific thoughts (Science) and new technological developments (Technology) of bio-pharmaceuticals, to provide the rapidly developing bio-pharma industry a platform to regularly showcase itself and get the latest information of the industry.

Concurrently with the exhibition, Bio S&T will hold three-day high-end biotechnology meetings, to keep track of the development trends of the bio-medicine industry in recent years; it will invite over 30 senior pharmaceutical experts inside and outside China to form a luxury speaker lineup to combine meeting and exhibition through the three topics of therapeutic monoclonal antibodies, GMP production of macromolecular biopharmaceutical products, and biotechnology investment, and will gather individuals and enterprises, and upstream and downstream experts and users to conduct multidimensional exchanges and interactions; it will drive development through technological innovation, and achieve win-win through mutually beneficial cooperation, to boost the bio-pharma industry to flourish.

Visit the exhibition website http://www.cphi-china.cn/biolive/ennow to register online and join the annual event of the biopharmaceutical industry, and have face-to-face exchanges with the industry giants!

bioLIVE China 2019 
June 18-20, 2019, SNIEC, Shanghai, China
Organizer: UBM EMEA, CCCMHPIE
Co-organizer: UBM Sinoexpo
"
  ["description"]=>
  string(5097) "
The bio-pharma industry has entered the new stage of rapid development in recent years with the continuous development of the cutting-edge biological technology and the emerging and marketing of new targeted drugs and cell therapies, etc.
From the perspective of global market size, sales of the global biotech drugs are expected to account for more than one third of all the sales revenue of pharmaceutical products by 2020. According to the statistics of InSight, in 2017, the biological drug applications reached the highest level in China in recent 5 years, with a total of 616. And Frost & Sullivan forecasts that the biological drug market size will reach RMB 326.9 billion in China in 2021, with the growth rate ranking high in the world.

The bio-pharma display platform with 7 years of historical accumulation in China—BioPh China will be newly upgraded into bioLIVE China on June 18-20, 2019. bioLIVE China 2019 will focus on life science, biotechnology, and innovative drugs, lead the bio-medicine technology innovation and industry development, and interact with industry high-end conferences. Together with CPhI China 2019 in SNIEC, bioLIVE China will jointly create a leading whole-industry-chain annual gala of the pharmaceutical industry in Asia
To comprehensively showcase the industry’s leading technologies, with the participation of 150+ bio-pharma exhibitors
bioLIVE China 2019 will gather top biopharmaceutical products and R&D information inside and outside China, and is expected to attract 150+ well-known enterprises including 3SBio, Sinobioway, Dongbao Pharmaceutical, Gan & Lee Pharmaceuticals, GenScript Biotech, Hualan Bio, Hybio Pharmaceutical, and Frontier Biotechnologies to join. It is becoming a first choice for bio-pharma enterprises to publicize brands and expand markets, by virtue of the exhibition platform advantages of high internationalization degree and full coverage of the pharmaceutical industry!

bioLIVE China 2019, a leader in Asian biopharmaceutical exhibitions, will centrally showcase advanced technologies in the three areas: biological products and emerging therapies; bioprocessing, manufacturing and solutions; and biotechnology and R&D services. It is expected to gather more than 20,000 Chinese and overseas professional buyers and researchers in Shanghai, to provide professionals in biotechnology, new drug R&D, and pharmaceutical investment areas, etc. with an industry-leading platform for information exchange and international trade expansion.
To gather Chinese and overseas experts, and initiate a top summit forum of the bio-pharma industry
bioLIVE China will enter into deep cooperation with international professional biotechnology organizations, bio-pharma enterprises, and high-end bio-pharma technological and financial talents in 2019, to roll out the industry top summit forum—Bio S&T which will focus on the new scientific thoughts (Science) and new technological developments (Technology) of bio-pharmaceuticals, to provide the rapidly developing bio-pharma industry a platform to regularly showcase itself and get the latest information of the industry.

Concurrently with the exhibition, Bio S&T will hold three-day high-end biotechnology meetings, to keep track of the development trends of the bio-medicine industry in recent years; it will invite over 30 senior pharmaceutical experts inside and outside China to form a luxury speaker lineup to combine meeting and exhibition through the three topics of therapeutic monoclonal antibodies, GMP production of macromolecular biopharmaceutical products, and biotechnology investment, and will gather individuals and enterprises, and upstream and downstream experts and users to conduct multidimensional exchanges and interactions; it will drive development through technological innovation, and achieve win-win through mutually beneficial cooperation, to boost the bio-pharma industry to flourish.

Visit the exhibition website http://www.cphi-china.cn/biolive/ennow to register online and join the annual event of the biopharmaceutical industry, and have face-to-face exchanges with the industry giants!

bioLIVE China 2019 
June 18-20, 2019, SNIEC, Shanghai, China
Organizer: UBM EMEA, CCCMHPIE
Co-organizer: UBM Sinoexpo
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(5) "Admin"
  ["added_by"]=>
  string(5) "Admin"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  NULL
  ["rss_id"]=>
  NULL
  [14]=>
  string(128) "https://pharmaxcareers.com/bioLIVE-China-2019-to-be-Newly-Upgraded,-to-Lead-the-Development-of-the-Bio-Pharma-Technology-in-Asia"
  ["blog_url"]=>
  string(128) "https://pharmaxcareers.com/bioLIVE-China-2019-to-be-Newly-Upgraded,-to-Lead-the-Development-of-the-Bio-Pharma-Technology-in-Asia"
  [15]=>
  string(19) "2019-01-16 08:33:23"
  ["add_date"]=>
  string(19) "2019-01-16 08:33:23"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-16 08:33:23"
  ["create_at"]=>
  string(19) "2019-01-16 08:33:23"
  [19]=>
  string(100) "biolive_china_2019_to_be_newly_upgraded_to_lead_the_development_of_the_bio-pharma_technology_in_asia"
  ["slug"]=>
  string(100) "biolive_china_2019_to_be_newly_upgraded_to_lead_the_development_of_the_bio-pharma_technology_in_asia"
}

bioLIVE China 2019 to be Newly Upgraded, to Lead the Development of the Bio-Pharma Technol

The bio-pharma industry has entered the new stage of rapid development in recent years with the continuou

array(40) {
  [0]=>
  string(4) "1663"
  ["article_id"]=>
  string(4) "1663"
  [1]=>
  string(44) "AHA Suggests Ways to Mitigate Drug Shortages"
  ["article_title"]=>
  string(44) "AHA Suggests Ways to Mitigate Drug Shortages"
  [2]=>
  string(153) "&#nl        The American Hospital Association urged the FDA to seek authority from Congress to require more stringent disclosures by drugmakers to help l"
  ["short_description"]=>
  string(153) "&#nl        The American Hospital Association urged the FDA to seek authority from Congress to require more stringent disclosures by drugmakers to help l"
  [3]=>
  string(196) "&#nl        The American Hospital Association urged the FDA to seek authority from Congress to require more stringent disclosures by drugmakers to help limit prescription drug shortages.&#nl      "
  ["description"]=>
  string(196) "&#nl        The American Hospital Association urged the FDA to seek authority from Congress to require more stringent disclosures by drugmakers to help limit prescription drug shortages.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(84) "https://www.fdanews.com/articles/189889-aha-suggests-ways-to-mitigate-drug-shortages"
  ["blog_url"]=>
  string(84) "https://www.fdanews.com/articles/189889-aha-suggests-ways-to-mitigate-drug-shortages"
  [15]=>
  string(19) "2019-01-16 06:54:28"
  ["add_date"]=>
  string(19) "2019-01-16 06:54:28"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-21 08:05:21"
  ["create_at"]=>
  string(19) "2019-01-21 08:05:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

AHA Suggests Ways to Mitigate Drug Shortages

&#nl The American Hospital Association urged the FDA to seek authority from Congress to require more stringent di

array(40) {
  [0]=>
  string(4) "1664"
  ["article_id"]=>
  string(4) "1664"
  [1]=>
  string(79) "Lawmakers Want Probe of BMS/Celgene Deal’s Effect on Competition, Prices"
  ["article_title"]=>
  string(79) "Lawmakers Want Probe of BMS/Celgene Deal’s Effect on Competition, Prices"
  [2]=>
  string(168) "&#nl        Two U.S. Representatives — one a Republican, the other a Democrat — are calling for a government probe into how Bristol-Myers Squibb’s "
  ["short_description"]=>
  string(168) "&#nl        Two U.S. Representatives — one a Republican, the other a Democrat — are calling for a government probe into how Bristol-Myers Squibb’s "
  [3]=>
  string(262) "&#nl        Two U.S. Representatives — one a Republican, the other a Democrat — are calling for a government probe into how Bristol-Myers Squibb’s planned $74 billion acquisition of Celgene could affect competition and drug prices.&#nl      "
  ["description"]=>
  string(262) "&#nl        Two U.S. Representatives — one a Republican, the other a Democrat — are calling for a government probe into how Bristol-Myers Squibb’s planned $74 billion acquisition of Celgene could affect competition and drug prices.&#nl      "
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "16"
  ["rss_id"]=>
  string(2) "16"
  [14]=>
  string(109) "https://www.fdanews.com/articles/189888-lawmakers-want-probe-of-bmscelgene-deals-effect-on-competition-prices"
  ["blog_url"]=>
  string(109) "https://www.fdanews.com/articles/189888-lawmakers-want-probe-of-bmscelgene-deals-effect-on-competition-prices"
  [15]=>
  string(19) "2019-01-16 06:53:47"
  ["add_date"]=>
  string(19) "2019-01-16 06:53:47"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-21 08:05:21"
  ["create_at"]=>
  string(19) "2019-01-21 08:05:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Lawmakers Want Probe of BMS/Celgene Deal’s Effect on Competition, Prices

&#nl Two U.S. Representatives — one a Republican, the other a Democrat — are calling for a governme

array(40) {
  [0]=>
  string(4) "1640"
  ["article_id"]=>
  string(4) "1640"
  [1]=>
  string(95) "New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States"
  ["article_title"]=>
  string(95) "New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States"
  [2]=>
  string(150) "TOKYO and STAMFORD, Conn. – January 15, 2019 – Eisai Co., Ltd. (CEO: Haruo Naito, “Eisai”) and Purdue Pharma L.P. (President a"
  ["short_description"]=>
  string(150) "TOKYO and STAMFORD, Conn. – January 15, 2019 – Eisai Co., Ltd. (CEO: Haruo Naito, “Eisai”) and Purdue Pharma L.P. (President a"
  [3]=>
  string(251) "TOKYO and STAMFORD, Conn. – January 15, 2019 – Eisai Co., Ltd. (CEO: Haruo Naito, “Eisai”) and Purdue Pharma L.P. (President and CEO: Craig Landau, MD, “Purdue Pharma”) today announced that a new drug application..."
  ["description"]=>
  string(251) "TOKYO and STAMFORD, Conn. – January 15, 2019 – Eisai Co., Ltd. (CEO: Haruo Naito, “Eisai”) and Purdue Pharma L.P. (President and CEO: Craig Landau, MD, “Purdue Pharma”) today announced that a new drug application..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "9"
  ["rss_id"]=>
  string(1) "9"
  [14]=>
  string(188) "https://www.drugs.com/nda/lemborexant_190115.html?utm_source=ddc&utm_medium=rss&utm_campaign=New+Drug+Application+for+Insomnia+Disorder+Treatment+Lemborexant+Submitted+in+the+United+States"
  ["blog_url"]=>
  string(188) "https://www.drugs.com/nda/lemborexant_190115.html?utm_source=ddc&utm_medium=rss&utm_campaign=New+Drug+Application+for+Insomnia+Disorder+Treatment+Lemborexant+Submitted+in+the+United+States"
  [15]=>
  string(19) "2019-01-16 06:01:40"
  ["add_date"]=>
  string(19) "2019-01-16 06:01:40"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-21 08:05:17"
  ["create_at"]=>
  string(19) "2019-01-21 08:05:17"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United S

TOKYO and STAMFORD, Conn. – January 15, 2019 – Eisai Co., Ltd. (CEO: Haruo Naito, “Eisai”) and P

array(40) {
  [0]=>
  string(4) "1655"
  ["article_id"]=>
  string(4) "1655"
  [1]=>
  string(61) "Palliative Care Formulary now available on MedicinesComplete "
  ["article_title"]=>
  string(61) "Palliative Care Formulary now available on MedicinesComplete "
  [2]=>
  string(155) "The Palliative Care Formulary is now available on MedicinesComplete, following the Royal Pharmaceutical Society’s acquisition of its publisher, Pall"
  ["short_description"]=>
  string(155) "The Palliative Care Formulary is now available on MedicinesComplete, following the Royal Pharmaceutical Society’s acquisition of its publisher, Pall"
  [3]=>
  string(187) "The Palliative Care Formulary is now available on MedicinesComplete, following the Royal Pharmaceutical Society’s acquisition of its publisher, PalliativeDrugs.com, in August 2018."
  ["description"]=>
  string(187) "The Palliative Care Formulary is now available on MedicinesComplete, following the Royal Pharmaceutical Society’s acquisition of its publisher, PalliativeDrugs.com, in August 2018."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "11"
  ["rss_id"]=>
  string(2) "11"
  [14]=>
  string(125) "https://www.pharmaceutical-journal.com/your-rps/palliative-care-formulary-now-available-on-medicinescomplete/20206003.article"
  ["blog_url"]=>
  string(125) "https://www.pharmaceutical-journal.com/your-rps/palliative-care-formulary-now-available-on-medicinescomplete/20206003.article"
  [15]=>
  string(19) "2019-01-15 23:16:00"
  ["add_date"]=>
  string(19) "2019-01-15 23:16:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-21 08:05:18"
  ["create_at"]=>
  string(19) "2019-01-21 08:05:18"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Palliative Care Formulary now available on MedicinesComplete

The Palliative Care Formulary is now available on MedicinesComplete, following the Royal Pharmaceutical Society’s

array(40) {
  [0]=>
  string(4) "1656"
  ["article_id"]=>
  string(4) "1656"
  [1]=>
  string(85) "Pharmacy2U dispensed nearly a quarter of a million prescriptions monthly in 2017/2018"
  ["article_title"]=>
  string(85) "Pharmacy2U dispensed nearly a quarter of a million prescriptions monthly in 2017/2018"
  [2]=>
  string(160) "The UK’s largest online pharmacy dispensed an average of nearly a quarter of a million items every month in 2017/2018 — more than any other distan"
  ["short_description"]=>
  string(160) "The UK’s largest online pharmacy dispensed an average of nearly a quarter of a million items every month in 2017/2018 — more than any other distan"
  [3]=>
  string(180) "The UK’s largest online pharmacy dispensed an average of nearly a quarter of a million items every month in 2017/2018 — more than any other distance-selling pharmacy."
  ["description"]=>
  string(180) "The UK’s largest online pharmacy dispensed an average of nearly a quarter of a million items every month in 2017/2018 — more than any other distance-selling pharmacy."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "11"
  ["rss_id"]=>
  string(2) "11"
  [14]=>
  string(164) "https://www.pharmaceutical-journal.com/news-and-analysis/news/pharmacy2u-dispensed-nearly-a-quarter-of-a-million-prescriptions-monthly-in-2017/2018/20205999.article"
  ["blog_url"]=>
  string(164) "https://www.pharmaceutical-journal.com/news-and-analysis/news/pharmacy2u-dispensed-nearly-a-quarter-of-a-million-prescriptions-monthly-in-2017/2018/20205999.article"
  [15]=>
  string(19) "2019-01-15 22:59:00"
  ["add_date"]=>
  string(19) "2019-01-15 22:59:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-01-21 08:05:18"
  ["create_at"]=>
  string(19) "2019-01-21 08:05:18"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Pharmacy2U dispensed nearly a quarter of a million prescriptions monthly in 2017/2018

The UK’s largest online pharmacy dispensed an average of nearly a quarter of a million items every month in 2017/

array(40) {
  [0]=>
  string(4) "4498"
  ["article_id"]=>
  string(4) "4498"
  [1]=>
  string(25) "TMB & Neoantigen Congress"
  ["article_title"]=>
  string(25) "TMB & Neoantigen Congress"
  [2]=>
  string(162) "EXPLORING ADVANCEMENTS IN NOVEL TARGETS, PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE&#nl&#nl &#nl&#nlOne of the key advantages of immuno-oncology is the poten"
  ["short_description"]=>
  string(162) "EXPLORING ADVANCEMENTS IN NOVEL TARGETS, PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE&#nl&#nl &#nl&#nlOne of the key advantages of immuno-oncology is the poten"
  [3]=>
  string(519) "EXPLORING ADVANCEMENTS IN NOVEL TARGETS, PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE&#nl&#nl &#nl&#nlOne of the key advantages of immuno-oncology is the potential to offer targeted personalized care for patients. However, challenges remain in matching patients to the therapies that offer the greatest chance of success, limiting efficacy depending on individual circumstances and increasing costs. Thus technologies that can assist in guiding therapies are vital – a role filled by predicted biomarker an..."
  ["description"]=>
  string(519) "EXPLORING ADVANCEMENTS IN NOVEL TARGETS, PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE&#nl&#nl &#nl&#nlOne of the key advantages of immuno-oncology is the potential to offer targeted personalized care for patients. However, challenges remain in matching patients to the therapies that offer the greatest chance of success, limiting efficacy depending on individual circumstances and increasing costs. Thus technologies that can assist in guiding therapies are vital – a role filled by predicted biomarker an..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(55) "https://www.pharmiweb.com/event/tmb-neoantigen-congress"
  ["blog_url"]=>
  string(55) "https://www.pharmiweb.com/event/tmb-neoantigen-congress"
  [15]=>
  string(19) "2019-01-15 20:54:38"
  ["add_date"]=>
  string(19) "2019-01-15 20:54:38"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-09-14 14:32:21"
  ["create_at"]=>
  string(19) "2019-09-14 14:32:21"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

TMB & Neoantigen Congress

EXPLORING ADVANCEMENTS IN NOVEL TARGETS, PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE&#nl&#nl &#nl&#nlOne of the key